Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

“科研圈日报”主要关注科研圈与研究者个体、科研圈与更广阔的社会环境之间的重要互动。点击 这里 可以查看往期内容。· 科学突破《科学》公布 2024 年度十大突破，SpaceX“筷子夹火箭”入选，长效艾滋病预防药物位列榜首图片来源：SpaceX当地时间 ...

在激烈的生物医药竞争中，Assembly Biosciences（纳斯达克代码：ASMB）最近传出了振奋人心的消息。该公司专注于开发针对严重病毒性疾病的创新疗法，并于19日宣布获得了巨头吉利德科学（Gilead Sciences）2010万美元的股权投资。这笔投资不仅提升了吉利德对Assembly Bio的持股比例至29.9%，同时还包括1000万美元的加速资金，用于推动新型抗病毒疗法的研发。

01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...